Amicus Therapeutics Inc. (FOLD): Palo Alto Investors Sells Half of its Stake At Sky-High Valuation
William Leland Edwards’ Palo Alto Investors disclosed today a 50% decrease in its exposure to Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Intermune Inc (ITMN)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Moab Capital Partners Michael M. Rothenberg | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | GAMCO Investors Mario Gabelli | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.37 | 4,950 | $71,129.52 | 14,158 | 2013-08-27 | Filing | |
| $15.00 | 1,650 | $24,743.07 | 9,208 | 2013-08-26 | Filing | |
| $13.27 | 8,308 | $110,247.16 | 51,974 | 2010-11-02 | Filing | |
| $14.10 | 2,127,660 | $30,000,006.00 | 9,485,209 | 2010-01-26 | Filing | |
| $14.10 | 2,127,660 | $30,000,006.00 | 9,485,209 | 2010-01-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.47 | 7,500 | $551,034.75 | 30,927 | 2014-09-02 | Filing | |
| $51.28 | 10,000 | $512,752.00 | 28,666 | 2014-08-15 | Filing | |
| $39.79 | 12,085 | $480,902.03 | 28,666 | 2014-06-04 | Filing | |
| $50.00 | 7,500 | $375,000.00 | 21,913 | 2014-08-13 | Filing | |
| $50.00 | 17,000 | $850,000.00 | 65,671 | 2014-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 59 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
InterMune Inc (ITMN), United Therapeutics Corporation (UTHR), Cyberonics Inc. (CYBX): Palo Alto Investors Loves Healthcare Stocks
Palo Alto Investors is a hedge fund founded by William Leland Edwards in 1989, and managed by him ever since.
Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)
Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.
Hedge Funds Are Dumping Dendreon Corporation (DNDN)
To the average investor, there are tons of methods shareholders can use to monitor the equity markets. Two of the most under-the-radar are hedge fund and insider trading interest.
Do Hedge Funds and Insiders Love Halozyme Therapeutics, Inc. (HALO)?
Now, according to many investors, hedge funds are seen as delayed, outdated financial tools of an era lost to time.
InterMune Inc (ITMN): Hedge Funds Aren't Crazy About It, Insider Sentiment Unchanged
To many market players, hedge funds are perceived as delayed, old financial tools of a period lost to current times.
Array Biopharma Inc (ARRY), InterMune Inc (ITMN): Three Humongous Health-Care Stocks This Week
The study included 184 patients with mild-to-moderate persistent allergic asthma. ARRY-502 met the study's primary endpoint of significant improvement in a key measure of lung function.
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it's earnings season again.
Cytokinetics, Inc. (CYTK), Exelixis, Inc. (EXEL): Three Small Cap Biotech Stocks with Great Potential
Small cap stocks are a bit riskier, but offer more growth than the stable large cap ones. The biotech sector in U.S.
Should You Buy InterMune Inc (ITMN)?
In the 21st century investor’s toolkit, there are plenty of methods investors can use to analyze stocks. Two of the most useful are hedge fund and insider trading interest.
Hedge Fund Resource Center